YSB (FRA:B1S) Research & Development: €11 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:B1S YSB Inc FRA:B1S
74 GF Score
Price €0.36
GF Value €0.74
! 5 Warning Signs
View Full Analysis

What is YSB Research & Development?

YSB FRA:B1S +3.49% 74 Research & Development is €11 Mil as of Jun. 2026. GuruFocus rates FRA:B1S with a GF Score™ of 74/100 and a GF Value™ of €0.74. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. YSB's Research & Development for the six months ended in Jun. 2026 was €6 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was €11 Mil.

YSB  (FRA:B1S) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

YSB Research & Development Related Terms

YSB Research & Development Historical Data

* Premium members only.

The historical data trend for YSB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

YSB Research & Development Chart

YSB Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 7.87 10.72 12.02 12.36 11.60

YSB Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 5.85 6.36 5.86 5.71 5.59
FRA:B1S
74GF Score
YSB Inc FRA:B1S
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

YSB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €11 Mil mean?
YSB (FRA:B1S) has a Research & Development of €11 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on YSB and its competitors.
Is YSB's Research & Development too high?
YSB's current Research & Development is €11 Mil. Overall, YSB has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does YSB's Research & Development compare to competitors?
YSB's Research & Development of €11 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on YSB and its competitors. YSB's current Research & Development is €11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is YSB stock overvalued right now?
YSB (FRA:B1S) has a current Research & Development of €11 Mil. The stock's GF Value™ is €0.74, compared to a current price of €0.36 — trading 51.9% below its estimated fair value. The current Research & Development is €11 Mil. YSB's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For YSB (FRA:B1S), the current Research & Development is €11 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is YSB (FRA:B1S) Overvalued in 2026?

Based on GuruFocus' analysis, YSB stock appears to be undervalued. The current stock price of €0.36 is trading 51.9% below its estimated GF Value™ of €0.74.

Key valuation signals for FRA:B1S:

  • Research & Development: €11 Mil
  • GF Value™: €0.74 vs. price of €0.36 (51.9% below fair value)
  • GF Score™: 74/100 with 5 warning signs

No single metric tells the full story. See the FRA:B1S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

YSB Business Description

Other Exchanges 09885:Hong Kong
Address No. 8 Brand Street, No. 397 Xingang Middle Road, Yaoshibang Building, TIT Creative Industry Zone, Guangzhou, CHN, 510310
YSB Inc is a digital pharmaceutical platform serving businesses outside of hospitals in China. The group is engaged in the wholesale and retail of pharmaceutical and healthcare products through offline channels, retail shops, and its online platform. It also operates an online marketplace that enables pharmaceutical distributors and vendors to sell pharmaceutical and healthcare products through the Group's platform. In addition, the Group provides SaaS solutions to downstream pharmacies and primary healthcare institutions to streamline inventory and patient management, and offers system technologies and operational support services through smart healthcare systems, integrated point-of-care testing and monitoring devices, digital management systems, and smart AI doctor-aid systems.
74GF Score

Get the complete analysis for FRA:B1S

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.36
Price
€0.74
GF Value